# Assessment of Safety, Tolerability, Radiation Dosimetry, Imaging Properties of 89Zr-girentuximab in Patients With NMIBC

> **NCT04897763** · EARLY_PHASE1 · COMPLETED · sponsor: **Institut Cancerologie de l'Ouest** · enrollment: 6 (actual)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** 89Zr-TLX250

## Key facts

- **NCT ID:** NCT04897763
- **Lead sponsor:** Institut Cancerologie de l'Ouest
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-15
- **Primary completion:** 2022-08-24
- **Final completion:** 2022-09-26
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2026-01-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04897763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04897763, "Assessment of Safety, Tolerability, Radiation Dosimetry, Imaging Properties of 89Zr-girentuximab in Patients With NMIBC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04897763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*